Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
Girndt M, Houser P, Manllo-Karim R, Ervin JE, Charytan C, Chow S, Symonian-Silver M, Lehrner L, Linfert D, Shemin D, Michelsen A, Xie F, Janssen RS. Girndt M, et al. Among authors: janssen rs. Vaccine. 2023 May 11;41(20):3224-3232. doi: 10.1016/j.vaccine.2023.04.028. Epub 2023 Apr 19. Vaccine. 2023. PMID: 37085451 Free article. Clinical Trial.
An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
Torales J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, Estigarribia G, Sanabria G, Lin MY, Antonio Estrada J, Estephan L, Cheng HY, Chen C, Janssen R, Lien CE. Torales J, et al. Vaccine. 2023 Jan 4;41(1):109-118. doi: 10.1016/j.vaccine.2022.10.030. Epub 2022 Nov 18. Vaccine. 2023. PMID: 36404171 Free PMC article. Clinical Trial.
Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.
Girndt M, Plüer M, Dellanna F, Michelsen AK, Beige J, Toussaint K, Wehweck HJ, Koch M, Hafezi Rachti S, Faust J, Bosselmann HP, Witzke O, Janssen RS; HBV-18 Study Investigators. Girndt M, et al. Among authors: janssen rs. Hum Vaccin Immunother. 2022 Nov 30;18(6):2136912. doi: 10.1080/21645515.2022.2136912. Epub 2022 Oct 21. Hum Vaccin Immunother. 2022. PMID: 36269938 Free PMC article. Clinical Trial.
An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis.
Awad AM, Ntoso A, Connaire JJ, Hernandez GT, Dhillon K, Rich L, Henderson H, Lynn R, Hyer RN, Xie F, Erby K, Janssen RS; HBV-24 Study Group. Awad AM, et al. Among authors: janssen rs. Vaccine. 2021 Jun 8;39(25):3346-3352. doi: 10.1016/j.vaccine.2021.05.003. Epub 2021 May 14. Vaccine. 2021. PMID: 34001345 Free article. Clinical Trial.
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. Ribas A, et al. Among authors: janssen rs. Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28. Cancer Discov. 2018. PMID: 30154193 Free PMC article. Clinical Trial.
Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, Shockey G, Akella L, Erby K, Heyward WL, Janssen RS; HBV-23 Study Group. Jackson S, et al. Among authors: janssen rs. Vaccine. 2018 Jan 29;36(5):668-674. doi: 10.1016/j.vaccine.2017.12.038. Epub 2017 Dec 27. Vaccine. 2018. PMID: 29289383 Free article. Clinical Trial.
86 results